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A B S T R A C T
The study of how human embryonic stem cells (hESCs) differentiate into insulin-producing beta cells has twofold significance: first, it provides an in vitro model system for the study of human pancreatic development, and second, it serves as a platform for the ultimate production of beta cells for transplantation into patients with diabetes. The delineation of growth factor interactions regulating pancreas specification from hESCs in vitro is critical to achieving these goals. In this study, we describe the roles of growth factors bFGF, BMP4 and Activin A in early hESC fate determination. The entire differentiation process is carried out in serum-free chemically-defined media (CDM) and results in reliable and robust induction of pancreatic endoderm cells, marked by PDX1, and cell clusters coexpressing markers characteristic of beta cells, including PDX1 and insulin/C-peptide.
Varying the combinations of growth factors, we found that treatment of hESCs with bFGF, Activin A and BMP4 (FAB) together for 3-4 days resulted in strong induction of primitivestreak and definitive endoderm-associated genes, including MIXL1, GSC, SOX17 and FOXA2.
Early proliferative foregut endoderm and pancreatic lineage cells marked by PDX1, FOXA2 and SOX9 expression are specified in EBs made from FAB-treated hESCs, but not from Activin A alone treated cells. Our results suggest that important tissue interactions occur in EBbased suspension culture that contribute to the complete induction of definitive endoderm and pancreas progenitors. Further differentiation occurs after EBs are embedded in Matrigel and cultured in serum-free media containing insulin, transferrin, selenium, FGF7, nicotinamide, islet neogenesis associated peptide (INGAP) and exendin-4, a long acting GLP-1 agonist. 21-28 days after embedding, PDX1 gene expression levels are comparable to those of human islets used for transplantation, and many PDX1 + clusters are formed. Almost all cells in PDX1 + clusters co-express FOXA2, HNF1ß, HNF6 and SOX9 proteins, and many cells also express CPA1, NKX6.1 and PTF1a. If cells are then switched to medium containing B27
and nicotinamide for 7-14 days, then the number of insulin + cells increases markedly. Our study identifies a new chemically defined culture protocol for inducing endoderm-and pancreas-committed cells from hESCs and reveals an interplay between FGF, Activin A and BMP signaling in early hESC fate determination.
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1.
Introduction
Human embryonic stem cells (hESCs) possess a strong proliferative ability and the potential to differentiate into all somatic cell types of the embryo and adult. As such, they provide an excellent platform for cell-based therapeutics and the study of human embryonic development. Mouse ESC studies have shown a correlation between the developmental pathways followed by cells in vitro and in vivo, and also between factors that induce and pattern ESCs and the embryo during differentiation (Tam et al., 2006; Jackson et al., 2010) . It is logical to assume that differentiation of hESCs in vitro mimics human embryonic development in vivo and can be used as a tool to study the mechanisms regulating cell fate decisions during development. Early studies defined the effects of single growth factors on hESCs differentiation fates (D'Amour et al., 2005; Schuldiner et al., 2000; Xu et al., 2002; Xu et al., 2005a) . However, given the knowledge that a limited number of different morphogens exert a diverse repertoire of effects in various tissues and at different stages of embryonic development in lower organisms, it seems obvious now to study combinatorial effects of different morphogens on tissue differentiation from hESCs. Several important studies in human pluripotent stem cells have begun to explore the interplay of multiple signaling pathways, including TGFß/Nodal/Activin, fibroblast growth factor (FGF), and bone morphogenetic protein (BMP) signaling on early fate decisions, and endoderm differentiation in particular (Vallier et al., 2009; Nostro et al., 2011; Rezania et al., 2011; Green et al., 2011) . As seemingly minor manipulations of similar protocols lead to divergent outcomes, we sought to further define the combinatorial effects of these signaling pathways on early endodermal cell fate decisions in hESCs and the ability to differentiate into pancreatic lineages.
As a member of the TGFß superfamily, Activin A has been reported to induce endoderm in Xenopus animal caps in vitro (Smith et al., 1990; Gamer and Wright, 1995; Ninomiya et al., 1999) ; in mouse ES cell differentiation Yasunaga et al., 2005) ; and in human ES cell differentiation cultures (D'Amour et al., 2005) . On the other hand, Beattie et al. (Beattie et al., 2005) and Vallier et al. (Vallier et al., 2005) showed that Activin A plays an important role in the maintenance of pluripotency of hESCs. It is intriguing that treatment with the same growth factor can result in such different fates. A confounding factor is probably insulin/insulinlike factor. In medium containing insulin, wherein the phosphatidylinositol 3-kinase (PI3K) signaling pathway is presumably activated, Activin A maintains the pluripotency of hESCs. Inhibition of the Activin signaling pathway with the Activin receptor inhibitor SB431542 results in hESC differentiation. However, when PI3K signaling is suppressed, Activin A induces definitive endoderm (DE) (McLean et al., 2007) . The interaction of growth factors is also observed with BMP4 in early hESC differentiation. Whereas BMP4 has been shown to promote trophectoderm differentiation of hESCs and blockade of BMP4 signaling is essential in maintaining the pluripotency of hESCs (Xu et al., 2002; Pera, 2004; Pera et al., 2004; Xu et al., 2005b) , we have found when BMP4 is combined with bFGF or Activin A, its induction of trophectoderm is greatly reduced.
Previous studies have found that BMP and FGF signaling modulate Activin-induced mesendoderm differentiation in mouse ES differentiation (Valdimarsdottir and Mummery, 2005; Morrison et al., 2008; Hansson et al., 2009 ). Vallier et al. (Vallier et al., 2009 ) presented a three-step protocol demonstrating that the combination of Activin, FGF and BMP signaling promotes hESC differentiation into mesendoderm. An FGF signaling inhibitor SU5402 is used in the second step of this three-step protocol. Results of our separate studies on early differentiation are consistent with Vallier's report. A recent paper by Nostro et al. ) also uses these growth factors, in combination with Wnt and VEGF, to induce endoderm differentiation from human pluripotent stem cells. Our protocol, which differs from both protocols in timing, growth factors used, and doses of growth factors, also demonstrates that a combination of bFGF, Activin A, and BMP4 (FAB) without insulin, in serum-free chemically-defined medium, results in reliable anterior primitive streak (APS)/DE production and FAB-treated cells can be further differentiated into pancreatic lineage cells.
The basic biology of these processes of further commitment of APS/DE to the pancreatic lineage and final maturation to endocrine cells are still poorly understood despite some knowledge from studies of other species (Vesque et al., 2000; Lammert et al., 2001; Kumar et al., 2003; Gu et al., 2002; Wells and Melton, 1999; Stafford et al., 2004; Lau et al., 2006) . Induction of posterior foregut is marked by expression of FOXA2, HNF1ß and HNF6 (D'Amour et al., 2006; Kroon et al., 2008) . Co-expression of SOX9 and PDX1 marks pancreatic commitment (Seymour et al., 2007) . Zhou et al. (Zhou et al., 2007) reported that a multipotent progenitor domain exists at the tip of the branching pancreatic tree in murine embryos. (Gradwohl et al., 2000) . Using information gathered from the literature regarding development of the pancreas, we have devised a unique 4 stage differentiation protocol, based on FAB treatment during the first stage and EB formation in the presence of FGF2 during the second stage (Fig. 1) 
Results

2.1.
Combined treatment with bFGF, Activin A and BMP4 in serum-free, chemically-defined media results in mesendoderm and APS/DE induction Our long-term objective is the differentiation of hESCs into pancreatic beta cells to be used as a transplantable cure for patients with Type 1 diabetes. It is widely believed that differentiation protocols that mimic in vivo developmental processes and begin with APS/DE formation will be the most successful in achieving this goal. Starting with a protocol aimed to initiate APS/DE formation involving treatment of hESCs with BMP4 and bFGF in conditioned medium, we ultimately developed a 4 stage protocol ( Fig. 1 ) in which cells are differentiated in chemically-defined media through stages that mimic pancreatic differentiation in embryos, to an endpoint of PDX1
Aiming to direct the differentiation of hESCs to APS/DE, we considered prior reports studying the effects of BMP4 on lineage differentiation from ESCs. In one paper, it was shown that BMP4 blocks neuroectoderm differentiation from mESCs (Ying et al., 2003) ; other reports suggest that BMP4 in combination with other growth factors, such as bFGF, results in mesendoderm and DE formation (Phillips et al., 2007; Willems and Leyns, 2008; Vallier et al., 2009; Micallef et al., 2007) and recently reviewed (Zorn and Wells, 2009) . Furthermore, data from nonmammalian systems indicate a potential role for BMP signaling in pancreatic endoderm formation (Kumar et al., 2003) .
We initially tested a differentiation protocol in which hESCs grown on Matrigel (MG) in MEF-conditioned medium (CM) were treated for 4 days with 10 ng/ml BMP4 and 100 ng/ml bFGF. Although growing cells for 7 days with a relatively high dose of BMP4 (100 ng/ml) induces differentiation into trophoblast cells expressing human chorionic gonadotrophin (hCG) (Supp. Fig. 1 and (Xu et al., 2002; Vallier et al., 2009) ), and treatment with 25 ng/ml BMP4 for 24 h results in mesoderm induction (Zhang et al., 2008) , treatment with an intermediate dose of 50 ng/ml BMP4 in combination with bFGF for 4 days resulted instead in significant increases in APS/DE gene expression, including GSC (p = 0.0002), MIXL1 (p < 0.0001), Brachyury (p < 0.0001), SOX17 (p < 0.0001), and FOXA2 (p = 0.0005) (Fig. 2) , when compared with undifferentiated hESCs. Increases in transcript levels for these five genes were much greater in cells treated with both BMP4 and bFGF, compared to conditions in which either factor was added alone, and hCG expression was lower in BMP4/bFGF treated cultures compared to high dose BMP4 alone treated cells (Supp. Fig. 1 ). Thus, bFGF can inhibit or partially override Data are shown as fold change versus undifferentiated hESCs grown with 4 ng/ml bFGF ( * , far left condition). Other growth factor concentrations: bFGF, 100 ng/ml; Activin A, 100 ng/ml; BMP4, 50 ng/ml; Activin inhibitor SB431542, 10 lM; Insulin, 5 lg/ml; FGF receptor inhibitor PD173074, 100 nM; PI3K inhibitor LY294003, 50 lM. Error bars represent standard error; results are combined from 3-9 independent experiments. The expressions of each gene among different groups were compared using analysis of variance (ANOVA) with pair-wise comparisons using Fisher's least significant difference tests. P-values are indicated in the text where relevant.
the ability of BMP4 to induce trophoblast, and together, bFGF and BMP4 appear to promote an APS/mesendoderm fate, as characterized by expression of Brachyury, GSC, MIXL1 and SOX17. However, expression of the trophectoderm marker CDX2 is still present (Supp. Fig. 2 ), suggesting that not all cells have adopted an APS fate.
Further differentiation of BMP4/bFGF treated cells through Stage 2 and Stage 3 resulted in cultures containing cells positive for PDX1/Insulin/C-peptide (Supp. Fig. 3 ), as well as cells expressing somatostatin or glucagon (Supp. Fig. 4) . Addition of the BMP4 antagonist noggin during Stage 1 led to significantly reduced levels of expression of SOX17, FOXA2, Brachyury, and PDX1 at the end of stage 2, suggesting that the observed differentiation requires BMP4 signaling (Supp. Fig. 5 ).
These observations suggested that BMP4 and bFGF were sufficient to induce DE from hESCs; however, the role of Activin A in this process is indisputable (D'Amour et al., 2005; Hansson et al., 2009; Vallier et al., 2009) . Activin A activity is present in undifferentiated ESC cultures grown on MEFS, as it has been suggested that bFGF treatment of MEFs may induce MEFs to secrete Activin A (Greber et al., 2007; Greber et al., 2010) . Hence, to further characterize the mechanism of mesendoderm promotion by BMP4 and bFGF, we examined the role of Activin A in Stage 1 of our differentiation protocol, by adding the Activin receptor inhibitor SB431542 to cells treated with bFGF + BMP4 in CM. This treatment completely inhibited expression of GSC (p = 0.4204), MIXL1 (p = 0.89710, T (p = 0.2113), and FOXA2 (p = 0.1271) (Fig. 2) , which was not significantly different from that of undifferentiated hESCs. This finding indicates that the differentiation to a mesendoderm fate occurs through the activation of the Activin pathway. Although no exogenous Activin A was added to our media, both CM and Matrigel contain Activin A/TGFb activity (Vukicevic et al., 1992; Beattie et al., 2005) . Indeed, when unconditioned media (UM) was substituted for CM, the inductive effect of bFGF + BMP4 on SOX17, FOXA2, and Brachyury was lost (data not shown).
Recent papers have shown that Activin A promotes DE differentiation from hESCs but that this occurs only when PI3K signaling pathway is inhibited (McLean et al., 2007) . When we found that adding Activin A to CM did not improve the differentiation of hESCs to mesendoderm, we posited this was due to the presence of insulin, a PI3K agonist, which is a component of SR, contained in this media. Thus, we studied gene expression in Activin A treated cultures in the presence and absence of insulin. When Activin A is combined with insulin, the induction of SOX17 is significantly decreased (p = 0.0154) and induction of Brachyury is significantly increased at the first stage (p = 0.0017). Thus, it appears insulin promotes or perhaps maintains mesendoderm (T), as well as further mesoderm differentiation (MEOX1 and TBX6 and KDR) but inhibits DE differentiation (CXCR4; Supp. Fig. 6 ).
To date, many published protocols that use Activin A treatment to induce DE differentiation include a small amount of FBS (D'Amour et al., 2005) , or use primarily low dose Activin A which is known to favor mesoderm fates (Vallier et al., 2009 ). To determine whether treatment with Activin A alone is sufficient to promote differentiation from APS through pancreatic endoderm to pancreatic endocrine cells in our protocol, we developed a chemically-defined serum free medium (CDM). Cells grown in CDM supplemented with Activin A alone showed significant induction of MIXL1, GSC, T, SOX17 and FOXA2 (p < 0.0001 compared to undifferentiated cells in CM; Fig. 2 ). Despite this promising early differentiation, EBs formed from Activin A-treated hESCs failed to develop. Thus, it was impossible to assess these cells in later stages of differentiation. We next tried treating cells with bFGF + BMP4 in CDM, and found good expression of SOX17 and T, although levels of MIXL1, GSC, and FOXA2 expression were much lower than in cultures treated with Activin A (Fig. 2) . However, when the three growth factors were combined (bFGF + Activin A + BMP4, hereafter referred to as FAB), expression levels of all five transcripts were comparable to or greater than those seen with Activin A alone (Fig. 2) , a finding that is consistent with the DE induction achieved by different Activin, bFGF, and BMP4 based serum-free protocols Vallier et al., 2009; Rezania et al., 2011; Green et al., 2011) . Immunostaining confirmed the expression of FOXA2, SOX17, and T at the protein level ( Fig. 3 and Supp. Fig. 7 ) following this treatment. Whereas the SOX17 and FOXA2 staining was similar among the groups tested, there appears to be a greater proportion of T +
Foxa2
À cells in cultures grown in FAB, FAB + insulin, and BMP4 + Activin A compared with cells treated with Activin A alone (Supp. Fig. 7 ), which correlates with the ability of the treated cells to form EBs, as described above. In addition, FAB-treated cells show upregulation of T and NKX2.5 transcripts, but not KDR or TBX6 transcripts compared to undifferentiated cells (Supp. Fig. 8 ). Thus, it is possible that mesoderm produced at Stage 1 and/or during EB formation allows definitive endoderm cells to survive, as has been hypothesized previously in murine and human ESC systems (Xu et al., 2006) . Activin A also inhibited the ability of BMP4 to induce differentiation of hESCs to trophoblasts. CDX2, an early marker of trophoblast differentiation induced by treatment with bFGF + BMP4, is not expressed when cultures are grown in FAB (Supp. Fig. 2) .
We assessed the effect of the PD173074, a specific inhibitor of FGF receptor signaling (Bansal et al., 2003) , on FABtreated cells. Transcript levels of GSG, MIXL1, SOX17, and FOXA2 are reduced dramatically following addition of 100 nM PD173074 (Fig. 2) , suggesting that signaling controlled by bFGF is important in this differentiation protocol. To confirm the role of PI3K in endoderm differentiation, we added the PI3K inhibitor LY294002 during FAB treatment, and analyzed gene expression after three days. We found that specific PI3K inhibition with 50 lM LY294002 did not have a dramatic effect on transcript levels of APS/DE genes when compared with FAB-treated cells: SOX17 and GSC expression were increased slightly, while T and FOXA2 expression were reduced somewhat (Fig. 2) . This is likely due to the fact that CDM is insulin-free, and is consistent with our result showing that insulin (a PI3K agonist) has an inhibitory effect on FAB-induced DE induction and enhances mesendoderm gene transcription (Fig. 2) . These results recapitulate the role of PI3K inhibition in endoderm formation from human pluripotent stem cells as first elucidated by McLean et al. (McLean et al., 2007) .
These findings confirm those of Vallier et al. (Vallier et al., 2009 ) who also identified the mesendoderm induction capabilities of the combination of BMP4, bFGF, and Activin A. Furthermore, EBs can be readily generated from FABtreated human ES cells, enabling further differentiation to pancreatic endoderm and endocrine cells (see Section 2.2). We therefore used FAB treatment in CDM for Stage 1 differentiation of hESCs to DE to test further differentiation strategies to pancreatic lineages.
2.2.
FAB-treated hESCs differentiated as embryoid bodies (EBs) begin to express pancreatic progenitor markers
Our previous experiments showed that differentiation through an EB stage, in which inductive tissue interactions may occur in three dimensions among the early embryonic germ layers, positively influences development of pancreatic lineage cells, compared to differentiation under two-dimensional conditions (Xu et al., 2006) . We have tried different Fig. 3 -Differentiation of hESCs to APS/DE following growth factor treatment. Cells were differentiated for 4 days (Stage 1) and then stained for SOX17 (red) and FOXA2 (green). Topro3 (blue) marks nuclei. Growth factor concentrations: bFGF, 100 ng/ml; Activin A, 100 ng/ml; BMP4, 50 ng/ml; insulin: 5 lg/ml. hESC = undifferentiated human ESCs grown in CM. Scale bars 50 lm. combinations of growth factors at different stages to get maximum expression of PDX1 and Insulin. Cells differentiated following our initial protocol of treatment with BMP4 + bFGF in CM in Stage 1 followed by growth as EBs in CM + bFGF (bFGF concentrations ranging from 20 ng/ml to 100 ng/ml) during Stage 2 resulted in a maximum level of PDX1 transcript accumulation at EB14 (14 days of suspension culture). In these cultures, the PDX1 transcript levels were comparable to the level of PDX1 expression in a 50% pure adult human islet preparation. Immunostaining showed a greatly increased number of PDX1 + cells, and some of these cells also expressed Ki67, suggesting PDX1 + cells are proliferative at this stage (Supp. Fig. 9 ).
In addition, many cells in these cultures expressed PTF1a. However, we found that this extremely strong expression of PDX1, even in conjunction with expression of PTF1a, did not lead to robust Insulin expression at later stages (data not shown To investigate further the differentiation potential of the cells grown through Stages 1 and 2, Stage 2 cells were plated in MG on coverslips in serum-free ITSFINE media containing insulin, transferrin, selenium, FGF7, INGAP, nicotinamide, and exendin 4 for an additional 21-28 days (Stage 3). These reagent additives were chosen rationally based on their defined properties as previously described in the literature. Duct-like structures started to form around day 14 of Stage 3 (not shown). Starting around day 21, sphere-like cell clusters were formed (Fig. 6, top) . Note that the cell clusters shown are not EBs; these cell clusters formed after plating. Immunostaining revealed that the cell clusters were highly enriched for FOXA2 (98% ±0.1%), SOX9 (95% ±0.03%), HNF6 (97% ±0.04%), HNF1b (100%) and PDX1 (97% ±0. (Fig. 7) , or Insulin (Fig. 8) .
Branch-like structures sometimes appear within cell-clusters, and are co-stained with PDX1 and CPA, and a substantial number of PDX1 + cells begin to express NGN3 at this stage (Fig. 7) . Cells outside of the cell clusters were never found to express these markers. Proliferating Ki67 + cells were found both within and outside of PDX1 + -sphere cells (Fig. 8) . In many areas of PDX1 + cells, there is coexpression of MafA, which is not seen outside the PDX1 + regions (Fig. 8) . Mature beta cells express MafA but not MafB (Nishimura et al., 2006) . In our hands, MafB staining has not been successful, so full interpretation of MafA staining is not possible. Insulin-positive cells were found within cell clusters throughout Stage 3, and co-stain with both PDX1 and C-peptide (not shown). At the end of Stage 3, the mean number of positive cells per culture well (in 24-well plates) is 168 ± 7. QPCR data suggest that Stage 1 treatment of hESCs influences their differentiation capacities at subsequent stages. For example, FAB treatment results in higher expression of PDX1 and FOXA2 at Stages 2 and 3 compared to CMBF or ITSFAB treatment (Fig. 4) and increased PDX1 transcript accumulation than observed in cells cultured using the D'Amour protocol (Supp. Fig. 10 ). The level of FOXA2 transcripts in FAB-treated cultures diminishes from Stage 2 to 3 (41-and 21-fold changes versus untreated spontaneously-differentiated EBs), whereas PDX1 transcripts increase from 175-to 1158-fold change in Stage 2 and 3, respectively, as would be expected if endoderm is further differentiating to the foregut/pancreas lineage. A timecourse of gene expression reveals that SOX9, HNF6, CPA, and NGN3 transcript levels are very low or undetectable in undifferentiated hESCs and Stage 1 cells. At Stage 2 there is a modest increase in SOX9 transcripts, and a 73-fold increase in HNF6 expression, compared with hESCs. By Stage 3, expression levels of each of these transcripts have increased compared to the baseline expression level: SOX9, 27.5-fold; HNF6, 311-fold; CPA, 13-fold; NGN3, 78-fold (Supp. Fig. 10 ).
A final differentiation stage encourages terminal differentiation and results in an increase in Insulin
+ cells
For Stage 4, ITSFINE media was switched to NB media (nicotinamide and B27) for an additional 5-14 days in order to promote endocrine differentiation. At the end of this stage, the Insulin content increased dramatically, both at transcript level (delta CT went from 9 to 5) and at protein level ( Fig. 4 ; Fig. 9 The Insulin + cells in these cultures also co-express C-peptide ( Fig. 9) , demonstrating that the cells are synthesizing Insulin and not taking it up from the media. The cultures also have many somatostatin-and glucagon-expressing cells (Fig. 9) . In some cases, these cells co-express Insulin, revealing that they are immature endocrine cells. However, the vast majority of Insulin + cells at this stage do not co-express other pancreatic hormone proteins. The literature (Cabrera et al., 2006) shows the ratio of Insulin endoderm-derived organs, including TAT, CDX1, and TITF1 (data not shown), suggesting that the differentiation promoted by this protocol is specific to pancreas.
Discussion
A better understanding of extrinsic signals regulating early fate choices of hESCs will drive the discovery of successful differentiation protocols for producing functional cell types for clinical applications. Here, we examine how bFGF, Activin A/Nodal, BMP4 (FAB) and insulin modulate mesendoderm and DE differentiation of hESCs grown under chemically defined conditions in adherent monolayer culture.
Prior reports exploring the effects of Activin/Nodal, FGF, and BMP signaling in mouse and human ESCs have yielded conflicting results which need to be resolved. Previous differentiation studies in human ESCs showed that the expression of GSC and other anterior primitive streak genes were induced by high dose Activin A but were prevented by treatment with BMP4 and concomitant inhibition of FGF signaling (D'Amour et al., 2005) . On the other hand, high dose BMP4 treatment alone readily promotes extra-embryonic endoderm or trophoblast lineage differentiation (Xu et al., 2005b; D'Amour et al., 2005) . However, studies in mESCs indicate that either BMP4 alone, Activin A alone or both together induced primitive streak markers, but that BMP4 exerts a dominant effect (Nostro et al., 2008; Jackson et al., 2010) . Other studies suggest that a BMP4/Activin-based culture protocol is useful for initiating the production of hESC-derived cardiomyocytes (Laflamme et al., 2007) . Similarly, short-term BMP4 treatment alone of hESCs promotes mesoderm differentiation (Zhang et al., 2008) , while Activin A alone treatment has been shown to maintain self-renewal properties (Xiao et al., 2006) and Activin A/Nodal and FGF coordinately maintain pluripotency in hESCs (Vallier et al., 2005) . On the other hand, Vallier et al. and others also studied the effects of stimulating or inhibiting BMP4, bFGF and Activin signaling pathways in hESCs and found that Activin signaling is permissive but not sufficient for differentiation of hESCs toward mesendoderm fate but the combination of all three factors efficiently induced mesendoderm differentiation (Vallier et al., 2009) . Like these earlier studies, our experimental results indicate that early cell fates are highly dependent on the combinatorial effects of these growth factors. We find that the induction of GSC, MIXL1, SOX17 and FOXA2 expression by Activin A is not adversely affected by the addition of BMP4. Moreover, adding both BMP4 and bFGF to Activin A-treated cells in serum/serum replacement-free defined media also maintains the expression of GSC, MIXL1, and FOXA2 induced by Activin A and further enhances the expression of T and SOX17. Importantly, hESCs grown in FAB media survive better than if they are differentiated in Activin A alone, and are able to form We find that insulin also plays a significant inhibitory role in early differentiation. Adding insulin to Activin A does not affect the induction of GSC and MIXL1, but significantly decreases the expression of SOX17 and FOXA2. Similar gene expression changes and reduced DE marker expression occurs when insulin is added to FAB. On the other hand, insulin enhances the expression of T and other mesoderm markers TBX6, MEOX1 and KGR. These gene expression changes can be interpreted as indicating that insulin signaling promotes hESC differentiation into primitive streak and mesendoderm, but not endoderm. Under these conditions, cells may be unable to exit the primitive streak fate, or may be pushed towards the mesoderm lineage. These findings and interpretation are consistent with previously published studies, such as those of McLean et al. who reported that insulin antagonizes DE differentiation of hESCs induced by Activin A (McLean et al., 2007) .
Our protocol leads to reliable production of sphereshaped cell clusters in which essentially all cells express HNF1b, HNF6, FOXA2, SOX9 and PDX1. This pattern of expression is consistent with a posterior foregut fate, and it remains a possibility that some cells within these spheres may adopt a stomach or intestine fate. However, it is clear that many cells within the PDX1 + -spheres are committed to a pancreas fate, as judged by their expression of NKX6.1, PTF1a, NGN3, MAFA, and CPA1, which is highly reminiscent of pancreatic progenitor epithelium (Oliver-Krasinski and Stoffers, 2008). The FAB-based culture protocol in chemically-defined media described here has been shown, in preliminary experiments, to yield similar quantities of DE and pancreatic progenitors from three human iPS cell lines, IMR-90, Foreskin and DF 19-9-7T (data not shown), in addition to hESC lines H1 and H9.
Endocrine hormone-producing cells were also generated in this differentiation protocol. Insulin, glucagon, and somatostatin were all found in these cell clusters. Although a small percentage of cells are polyhormonal, most hormone-positive cells express a single hormone and are in close relationship with each other. This is in contrast to a recent paper by Nostro et al., in which a majority of the C-peptide + cells generated from their protocol also express glucagon or glucagon and somatostatin . In our protocol described here, nearly all insulin + cells also were PDX1 + and C-peptide + , indicative of beta-like cells. Numerous functional studies suggest the importance of the three-dimensional structure of the islet and direct interactions between various islet endocrine cells, including beta cell-beta cell and beta cell-alpha cell interactions (Miller et al., 2009 + -spheres were considerably less robust than that seen in high glucose concentration containing media, such as DMEM/F12 (glucose concentration is 17.5 mM). Second, we observed an abnormal ratio of hormonal cells, i.e. a much higher percentage of somatostatin positive cells-to-insulin positive cells in hESC-derived pancreatic cells than in normal human islets. The third difference is that the insulin content of PDX1 + -spheres is considerably lower than that of islets.
Although the described methods generate numerous PDX1 + cells (transcript level is comparable to that in 50% pure human islets), and an easily detectable number of Insulin + cells, it has proven difficult to produce enriched populations of Insulin + cells despite testing many different growth factor supplements and media formulations as other studies have noted (D'Amour et al., 2006; Nostro et al., 2011; Rezania et al., 2011 (Jiang et al., 1999; Nikolova et al., 2006) . In human islets, the most prominent component of this matrix is laminin-511 (Otonkoski et al., 2008) . Another difference is the presence of two basement membranes surrounding blood vessels of human islets instead of a single membrane in murine islets (Otonkoski et al., 2008) . Matrigel is rich in mouse laminin-111 and was found to be essential for the induction of islet differentiation from expanded human pancreatic duct cells (Gao et al., 2003; Bonner-Weir et al., 2000) . These species differences may help guide further protocol modifications. In summary, the work presented here sheds light on the early signals regulating formation of primitive streak, mesendoderm and DE from hESCs, and in particular reveals an interplay between FGF, BMP, Activin/Nodal and insulin signaling. Three-dimensional PDX1 + -spheres are routinely formed in our culture system, which strongly resemble pancreatic progenitor epithelium. With these refined methods for producing enriched populations of pancreatic progenitors, we believe that efforts should be redoubled to better understand the extrinsic signaling promoting endocrine fate, including the generation of NGN3 + progenitors and conversion of these progenitors into functional endocrine cells.
Experimental procedures
4.1. Cell culture and differentiation NIH approved hESC lines, H1 (WA01) and H9 (WA09) were used between passage 18 to 42 and had normal karyotype checked by WiCell cytogenetics services (Madison, WI). Media for undifferentiated ESCs was comprised of 80% DMEM/F12 and 20% Knockout serum replacement supplemented with 1 mM L-glutamine, 1% nonessential amino acids, 0.1 mM 2-mercaptoethanol and 4 ng/ml bFGF (all from Invitrogen). hESCs were cultured in 6-well plates on a feeder layer of irradiated mouse embryonic fibroblasts (MEF) in either ESC media (control group), ESC media plus 50 ng/ml BMP4 (BMP4 group; R&D systems), or ESC media plus 50 ng/ml BMP4 plus 300 ng/ml noggin (noggin group; R&D systems) for 4 days. In experiments with Matrigel, hESCs were grown on growth-factor depleted Matrigel (BD Biosciences) instead of MEF and culture media was MEF-conditioned media (CM, control group), CM plus 50 ng/ ml BMP4 or CM plus 50 ng/ml BMP4 plus 100 ng/ml bFGF. In FAB experiments, hESCs plated on MG were cultured in chemically defined medium (CDM) containing DMEM/F12, 1 mM L-glutamine, 1% nonessential amino acids, 0.1 mM 2-mercaptoethanol and 2% BSA, supplemented with 100 ng/ml Activin A, 50 ng/ml BMP4 and 100 ng/ml bFGF for 3-4 days (stage 1), which were equally effective.
Colonies were transferred by incubating with 2 mg/ml dispase (Invitrogen) and put into 100-mm non-treated suspension culture dishes with CM or medium containing DMEM/ F12, ITS supplement (BD, 5 lg/ml insulin + 5 lg/ml transferrin + 5 ng/ml selenous acid), and 20-100 ng/ml bFGF on a shaker for 14 days to form embryoid bodies (EBs) (stage 2). EBs formed for 14 days were found to produce better pancreatic differentiation in later stages than 7 day EBs. EBs were then suspended in diluted Matrigel (0.66 mg/ml in cold DMEM/ F12) and replated in ITSFINE medium, a serum-free medium comprised of DMEM/F-12 (17.5 mM glucose) with ITS, 10 ng/ ml FGF7 (R&D), 10 mM nicotinamide (Sigma), 10 nM exendin-4 (Sigma), 4 lg/ml insulin, 200 nM INGAP (PSN-4765, sequence: IGLHDPSHGTLPNGS) and 2 g/L BSA (Sigma) for 14, 21 or 28 days (stage 3). Longer periods than 28 days under these conditions resulted in excessive cell detachment. At stage 4, media was switched to RPMI 1640 supplemented with B27 and nicotinamide for 4-14 days. A fraction of each culture from stage 3 and 4 was used for RT-PCR and Q-PCR and the remaining cells were either embedded in OCT (EB14; TissueTek) or fixed on coverslips for immunostaining. Media were collected at the end of stage 3 and 4 for the measurement of C-peptide levels.
4.2.
Quantitative PCR, RT-PCR, and C-peptide measurement Total cellular RNA was extracted with Trizol (Invitrogen). cDNA was synthesized from 1 lg total RNA using a SuperScript First-Strand Synthesis kit (Invitrogen). Quantitative real time RT-PCR (QPCR) was performed using Assays-on-demand reagents (Applied Biosystems) on a MyiQ Thermal Cycler (Bio-Rad). See Supplemental Table 1 for a list of the assay numbers. QPCR was performed according to the equipment manufacturer's instructions. Relative quantification was carried out using the comparative cycle threshold (C T ) method. Fold change was calculated as: 2 ÀDDCT . Mean DDC T values from QPCR analyses were compared using the unpaired, two-tailed Student's t-test unless noted otherwise. P values <0.05 were considered significant. hCG was measured on the Dade Behring Dimension Clinical Chemistry System, according to the instructions of the manufacturer.
For non-quantitative RT-PCR, oligonucleotide primer pairs were generated against human transcripts using Genbank sequences. See Supplemental Table 1 for primer sequences, amplicon sizes, and cycle numbers. Primers were selected from two exons that spanned at least one intronic sequence. PCR was performed using HotStarTaq DNA polymerase (Qiagen) and reaction conditions were as follows: initial denaturation at 95 C for 15 min, then cycles of 94°C for 30 s, at annealing temperature, 1 min at 72°C, and a final 10 min extension at 72°C. Primers were annealed at 53°C except for PDX1 (56°C), SOX17 (55°C) and FOXA2 (50°C; with Qiagen's Q-solution). A control sample without reverse transcriptase (-RT) was amplified with GAPDH primers in all cases, and human adult pancreas RNA was used as a positive control. Cpeptide levels in media from stage 3 or 4 cultures were measured using the ultrasensitive C-peptide ELISA (Mercodia).
4.3.
Immunofluorescence staining and cell counts
Immunofluorescence staining of coverslips was carried out as previously described (Kahan et al., 2003) . The following primary antibodies were used at the listed dilutions: PDX1 rabbit anti-mouse serum 1:4000 (gift of C. Wright); insulin guinea pig anti-human 1:200 (Linco); glucagon mouse monoclo- To determine the percentage of cells within PDX1 + -spheres that expressed specific proteins, cells were co-stained with the marker of interest and the nuclear marker Topro3. The number of positive cells for each antibody was determined by dividing the number of nuclei that stained with a given marker by the number of nuclei within each cell cluster, as marked by Topro3.
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